×
About 58,378 results

ALLMedicine™ Cirrhosis Center

Research & Reviews  18,248 results

Clinical and genetic features of congenital bile acid synthesis defect with a novel mut...
https://doi.org/10.1097/MD.0000000000029476
Medicine Pham AN, Thi KB et. al.

Jun 28th, 2022 - Congenital bile acid synthesis defect (BASD) is a rare disease caused by mutations in the aldo-keto reductase 1D1 gene, which encodes the primary Δ4-3-oxosteroid 5β-reductase enzyme. Early disease diagnosis is critical for early treatment with bil...

Investigational drugs in early clinical development for portal hypertension.
https://doi.org/10.1080/13543784.2022.2095259
Expert Opinion on Investigational Drugs; Rodrigues SG, Mendoza YP et. al.

Jun 28th, 2022 - Advanced chronic liver disease is considered a reversible condition after removal of the primary aetiological factor. This has led to a paradigm shift in which portal hypertension (PH) is a reversible complication of cirrhosis. The pharmacologic m...

Novel liver-targeting drug offers hope for AAT deficiency
https://www.mdedge.com/internalmedicine/article/255786/hepatology/novel-liver-targeting-drug-offers-hope-aat-deficiency
Sara Freeman

Jun 27th, 2022 - LONDON – The novel liver-targeting agent fazirsiran has fared well in a small, but significant, study looking at its ability to improve liver histology in adults with alpha-1 antitrypsin (AAT) deficiency. Not only were serum and liver levels of th.

Macrophage-specific fibroblast growth factor 12 promotes liver fibrosis progression in ...
https://doi.org/10.1002/hep.32640
Hepatology (Baltimore, Md.); Li S, Zhou B et. al.

Jun 27th, 2022 - Chronic liver diseases are associated with the development of liver fibrosis. Without treatment, liver fibrosis commonly leads to cirrhosis and hepatocellular carcinoma. Fibroblast growth factor 12 (FGF12) is an intracrine factor belonging to the ...

Global Trends and The Impact of Chronic Hepatitis B and C on Disability-Adjusted Life Y...
https://doi.org/10.1111/liv.15347
Liver International : Official Journal of the Internation... Veracruz N, Gish RG et. al.

Jun 27th, 2022 - Advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) therapies have improved morbidity and mortality, but global disparities in viral hepatitis outcomes remain. We evaluate global trends in the impact of HBV and HCV on disability adjust...

see more →

Guidelines  41 results

EASL Clinical Practice Guidelines on haemochromatosis.
https://doi.org/10.1016/j.jhep.2022.03.033
Journal of Hepatology; ,

Jun 7th, 2022 - Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropa...

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diag...
https://doi.org/10.1016/j.eprac.2022.03.010
Endocrine Practice : Official Journal of the American Col... Cusi K, Isaacs S et. al.

May 16th, 2022 - To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other...

EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombos...
https://doi.org/10.1016/j.jhep.2021.09.003
Journal of Hepatology; ,

Mar 19th, 2022 - The prevention and management of bleeding and thrombosis in patients with cirrhosis poses several difficult clinical questions. These Clinical Practice Guidelines have been developed to provide practical guidance on debated topics, including curre...

AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients ...
https://doi.org/10.1053/j.gastro.2021.08.015
Gastroenterology O'Shea RS, Davitkov P et. al.

Sep 29th, 2021 - AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.|2021|O'Shea RS,Davitkov P,Ko CW,Rajasekhar A,Su GL,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemical...

AGA Technical Review on Coagulation in Cirrhosis.
https://doi.org/10.1053/j.gastro.2021.09.004
Gastroenterology Intagliata NM, Davitkov P et. al.

Sep 29th, 2021 - AGA Technical Review on Coagulation in Cirrhosis.|2021|Intagliata NM,Davitkov P,Allen AM,Falck-Ytter YT,Stine JG,|adverse effects,therapeutic use,drug effects,blood,diagnosis,drug therapy,standards,chemically induced,blood,diagnosis,drug therapy,

see more →

Drugs  647 results see all →

Clinicaltrials.gov  2,375 results

Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
https://clinicaltrials.gov/ct2/show/NCT01581554

Jun 24th, 2022 - Chronic hepatitis B affects at least 1.5 million Americans and is a major cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma. Five oral antiviral agents have been licensed for use in chronic hepatitis B in the United States. ...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Low-Dose Danazol for the Treatment of Telomere Related Diseases
https://clinicaltrials.gov/ct2/show/NCT03312400

Jun 24th, 2022 - Telomere disease is caused by accelerated telomere attrition and results in multi-organ dysfunction. Telomeres are nucleotide repeats of non-coding DNA at the end of the chromosomes which function as protective caps to prevent erosion of genomic D...

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Jun 24th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
https://clinicaltrials.gov/ct2/show/NCT02400216

Jun 24th, 2022 - Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the syst...

see more →

News  1,985 results

Novel liver-targeting drug offers hope for AAT deficiency
https://www.mdedge.com/internalmedicine/article/255786/hepatology/novel-liver-targeting-drug-offers-hope-aat-deficiency
Sara Freeman

Jun 27th, 2022 - LONDON – The novel liver-targeting agent fazirsiran has fared well in a small, but significant, study looking at its ability to improve liver histology in adults with alpha-1 antitrypsin (AAT) deficiency. Not only were serum and liver levels of th.

Are Pain Meds the Only Option for Chronic Pain in Cirrhosis?
https://www.medscape.com/viewarticle/976207

Jun 27th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the...

Fatty Liver Disease Drives Rise in Liver Cancer Deaths
https://www.medscape.com/viewarticle/976213

Jun 27th, 2022 - LONDON ― Around the world, nonalcoholic fatty liver disease (NAFLD) has driven an increase in deaths from liver cancer over the past decade, overtaking alcoholic liver disease, hepatitis B, and hepatitis C, according to an analysis of the Global B...

Are pain meds the only option for chronic pain in cirrhosis?
https://www.mdedge.com/internalmedicine/article/255747/hepatology/are-pain-meds-only-option-chronic-pain-cirrhosis
Jim Kling

Jun 24th, 2022 - Pain is common in patients with cirrhosis, and its management presents significant challenges to health care providers, such as worries about GI bleeding, renal injury, falls, and hepatic encephalopathy. To address those issues, researchers at the.

HCC with Child-Pugh B cirrhosis: Nivolumab a promising first-line systemic treatment option
https://www.mdedge.com/fedprac/article/255709/hepatocellular-carcinoma/hcc-child-pugh-b-cirrhosis-nivolumab-promising-first

Jun 23rd, 2022 - Key clinical point: Nivolumab may serve as a first-line systemic treatment option in patients with hepatocellular carcinoma (HCC) and Child-Pugh B (CP-B) cirrhosis. Major finding: Patients receiving nivolumab vs.

see more →

Patient Education  55 results see all →